BACKGROUND AND PURPOSE: PV is increasingly used as treatment for osteoporotic VCFs. However, controversy exists as to whether PV increases the risk for new VCFs during follow-up. The purpose of our research was to assess the incidence of new VCFs in patients with acute VCFs randomized to PV and conservative therapy. MATERIALS AND METHODS: VERTOS II is a prospective multicenter randomized controlled trial comparing PV with conservative therapy in 202 patients. Incidence, distribution, and timing of new VCFs during follow-up were assessed from spine radiographs. In addition, further height loss during follow-up of treated VCFs was measured. RESULTS: After a mean follow-up of 11.4 months (median, 12.0; range, 1-24 months), 18 new VCFs occurred in 15 of 91 patients after PV and 30 new VCFs in 21 of 85 patients after conservative therapy. This difference was not significant (P = .44). There was no higher fracture risk for adjacent-versus-distant vertebrae. Mean time to new VCF was 16.2 months after PV and 17.8 months after conservative treatment (logrank, P = .45). The baseline number of VCFs was the only risk factor for occurrence (OR, 1.43; 95% CI, 1.05-1.95) and number (P = .01) of new VCFs. After conservative therapy, further height loss of treated vertebrae occurred more frequently (35 of 85 versus 11 of 91 patients, P < .001) and was more severe (P < .001) than after PV. CONCLUSIONS:Incidence of new VCFs was not different after PV compared with conservative therapy after a mean of 11.4 months' follow-up. The only risk factor for new VCFs was the number of VCFs at baseline. PV contributed to preservation of stature by decreasing both the incidence and severity of further height loss in treated vertebrae.
RCT Entities:
BACKGROUND AND PURPOSE: PV is increasingly used as treatment for osteoporotic VCFs. However, controversy exists as to whether PV increases the risk for new VCFs during follow-up. The purpose of our research was to assess the incidence of new VCFs in patients with acute VCFs randomized to PV and conservative therapy. MATERIALS AND METHODS: VERTOS II is a prospective multicenter randomized controlled trial comparing PV with conservative therapy in 202 patients. Incidence, distribution, and timing of new VCFs during follow-up were assessed from spine radiographs. In addition, further height loss during follow-up of treated VCFs was measured. RESULTS: After a mean follow-up of 11.4 months (median, 12.0; range, 1-24 months), 18 new VCFs occurred in 15 of 91 patients after PV and 30 new VCFs in 21 of 85 patients after conservative therapy. This difference was not significant (P = .44). There was no higher fracture risk for adjacent-versus-distant vertebrae. Mean time to new VCF was 16.2 months after PV and 17.8 months after conservative treatment (logrank, P = .45). The baseline number of VCFs was the only risk factor for occurrence (OR, 1.43; 95% CI, 1.05-1.95) and number (P = .01) of new VCFs. After conservative therapy, further height loss of treated vertebrae occurred more frequently (35 of 85 versus 11 of 91 patients, P < .001) and was more severe (P < .001) than after PV. CONCLUSIONS: Incidence of new VCFs was not different after PV compared with conservative therapy after a mean of 11.4 months' follow-up. The only risk factor for new VCFs was the number of VCFs at baseline. PV contributed to preservation of stature by decreasing both the incidence and severity of further height loss in treated vertebrae.
Authors: Mubin I Syed; Neel A Patel; Solomon Jan; Michael S Harron; Kamal Morar; Azim Shaikh Journal: AJNR Am J Neuroradiol Date: 2005 Jun-Jul Impact factor: 3.825
Authors: M B Pitton; S Herber; C Bletz; P Drees; N Morgen; U Koch; B Böhm; A Eckardt; C Düber Journal: Eur Radiol Date: 2007-07-19 Impact factor: 5.315
Authors: K F Layton; K R Thielen; C A Koch; P H Luetmer; J I Lane; J T Wald; D F Kallmes Journal: AJNR Am J Neuroradiol Date: 2007-04 Impact factor: 3.825
Authors: M P Staples; B M Howe; M D Ringler; P Mitchell; C H R Wriedt; J D Wark; P R Ebeling; R H Osborne; D F Kallmes; R Buchbinder Journal: Arch Osteoporos Date: 2015-08-14 Impact factor: 2.617
Authors: F Borgström; D P Beall; S Berven; S Boonen; S Christie; D F Kallmes; J A Kanis; G Olafsson; A J Singer; K Åkesson Journal: Osteoporos Int Date: 2014-11-08 Impact factor: 4.507
Authors: Jan Philipp Kolb; Rebecca A Kueny; Klaus Püschel; Andreas Boger; Johannes M Rueger; Michael M Morlock; Gerd Huber; Wolfgang Lehmann Journal: Eur Spine J Date: 2013-05-16 Impact factor: 3.134